Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200mcg Twice Daily, GW685698X 200mcg and 400mcg Once Daily in the Morning, and GW685698X 200mcg and 400mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) with Persistent Asthma
The primary objective of this study is to evaluate the relative efficacy and safety of once daily and twice daily dosing and of morning and evening dosing of GW685698X in adolescent and adult subjects...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development
MAJ Il y a 4 ans
HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of fluticasone furoate/GW642444 inhalation powder with GW642444m on the annual rate of exacerbations in subjects with chronic obstructive pulmonary disease
To evaluate safety and efficacy of FF/GW642444 50mcg/25mcg QD and FF/GW642444 100mcg/25mcg QD and FF/GW642444 200mcg/25mcg QD versus GW642444 25mcg QD on the annual rate of moderate and severe exacerb...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline R & D
MAJ Il y a 4 ans
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury
The primary objective of the study is to demonstrate the superiority of fondaparinux 2.5 mg (1.5 mg in patients with a creatinine clearance between 30 and 50 mL/min) once daily versus LMWH (nadropari...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A study to test possible drug interactions with a new drug for treating skin cancer
PART A-To evaluate the effect of repeat doses of GSK2118436 on the single dose PK of S-warfarin in subjects with BRAF mutant solid tumors. PART B & C-To evaluate the effect of repeat oral doses of an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Consumer Healthcare
MAJ Il y a 4 ans
A Longitudinal MRI Study of Changes in Regional Body Composition During Orlistat (60mg)-Assisted Dieting
To examine the use of MRI to assess change-from-baseline in visceral adipose tissue in overweight volunteers following 3 months of orlistat 60mg and a reduced calorie, low fat diet.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy
The primary objective is to evaluate progression free survival (PFS) of ofatumumab maintenance treatment versus no further treatment after remission induction in subjects with relapsed Chronic Lymphoc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline GmbH & Co. KG
MAJ Il y a 4 ans
Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) to healthy children aged 11 to 21 months
To evaluate GMT and seroconversion rate to VZV before and after intramuscular and subcutaneous injection of GSK’s MeMuRu-OKA vaccine.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator paroxetine and GW679769 in subjects with Major Depressive Disorder
Define profile of neurobiological and psychological response to GW679769 (80-120 mg/day) compared to placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II, randomised, open study to evaluate the immunogenicity and safety of a single or double-dose of the pandemic influenza candidate vaccine split virus formulation adjuvanted with AS03 given following a two-administration schedule 21 days apart in adults over 60 years of age
To evaluate the immunogenicity of the H5N1 vaccine administered as a single or double dose in terms of humoral immune response anti-haemagglutinin antibody and neutralizing antibody 21 days after ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix / Influsplit SSW (2013/2014 season), in adults 18 years of age and older
To evaluate the humoral response [anti- Haemagglutinin (HA) antibodies tested by Haemagglutination Inhibition (HI)] against each vaccine strain in adults 18-60 years and >60 years of age, 21 days afte...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
4
5
6
7
8
9
10
11
12
13
Suivant